fluconazole 50mg/5ml oral suspension
genus pharmaceuticals ltd - fluconazole - oral suspension - 10mg/1ml
metformin hydrochloride tablet, film coated
ingenus pharmaceuticals, llc - metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - metformin hydrochloride 500 mg - metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. metformin hydrochloride tablets are contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73 m2 ) [see warnings and precautions (5.1)]. - hypersensitivity to metformin. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. risk summary limited data with metformin hydrochloride tablets in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk [see data ]. there are risks to the mother and fetus associated with poorly controlled diabetes mellitus in pregnancy [see clinical considerations ]. no adverse developmental effects were observe
carboplatin injection, solution
ingenus pharmaceuticals, llc - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin 50 mg in 5 ml - initial treatment of advanced ovarian carcinoma carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. secondary treatment of advanced ovarian carcinoma carboplatin injection is indicated for the palliative treatment of patient
fluoxetine 20mg capsules
genus pharmaceuticals ltd - fluoxetine hydrochloride - oral capsule - 20mg
gliclazide 80mg tablets
genus pharmaceuticals ltd - gliclazide - oral tablet - 80mg
lorazepam 1mg tablets
genus pharmaceuticals holdings ltd - lorazepam - oral tablet - 1mg
lorazepam 2.5mg tablets
genus pharmaceuticals holdings ltd - lorazepam - oral tablet - 2.5mg
trihexyphenidyl 5mg tablets
genus pharmaceuticals holdings ltd - trihexyphenidyl hydrochloride - oral tablet - 5mg
tramadol 50mg capsules
genus pharmaceuticals ltd - tramadol hydrochloride - oral capsule - 50mg
zolpidem 5mg tablets
genus pharmaceuticals ltd - zolpidem tartrate - oral tablet - 5mg